Skip to content

Effect of Gokshuradi Taila Katibasti Followed by Ultrasound Therapy Versus Ultrasound Therapy Alone in Low Back Pain .

A Randomized Controlled Clinical Study of Effect of Gokshuradi Tail Katibasti Followed by Ultrasound Therapy Versus Ultrasound Therapy Alone in Pain Management of Katisandhigat Vata with Special Reference to Lumbar Spondylosis - Nil

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2026/04/109528
Enrollment
72
Registered
2026-04-28
Start date
Unknown
Completion date
Unknown
Last updated
2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M169- Osteoarthritis of hip, unspecified

Interventions

None listed

Sponsors

APMS Ayurved Mahavidyalaya, Sion
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Both male and female patients. 2.Patients aged between 20yrs and 70years. 3.Radiological evidence of lumbar spondylosis. 4.Presence of pain in lower back region for more than 3 months. 5.Patients must be suitable for Swedan (sudation therapy). 6.Patients must be eligible for ultrasound therapy. 7.Patients should be willing to adhere to the treatment protocol and follow-up assessments. 8.Patients must provide informed consent to participate in the study.

Exclusion criteria

Exclusion criteria: 1.Patients with rheumatoid arthritis, rheumatic fever, rheumatic heart disease, gouty arthritis, psoriatic arthritis, or sciatica. 2.Patients with congenital or acquired abnormalities affecting the lumbar spine. 3.Patients with recent or ongoing fractures 4.Patients suffering from infectious conditions such as tuberculosis (TB), carcinoma, or other serious infections ,undergoing systemic steroid therapy or other immunosuppressive treatments. 5.Patients with active local skin infections or dermatitis over the lumbar region, severe cardiovascular, renal, or hepatic conditions that could interfere with the treatment or assessment. 6.Pregnant or breastfeeding women. 7.Patients with a history of allergic reactions to any of the components used in the treatments.

Design outcomes

Primary

MeasureTime frame
Changes in clinical symptom such as Katishool from baseline to day 14Timepoint: baseline, 1 week & 2 weeks

Secondary

MeasureTime frame
nilTimepoint: nil

Countries

India

Contacts

Public ContactDr Datt Bapardekar

APMs Ayurved Mahavidyalaya Sion

panchakarm@gmail.com99691 19134

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Jun 11, 2026